⚠ Disclaimer: This report is generated using AI tools and is for informational purposes only. It does not constitute investment advice. Please consult a registered financial advisor before making any investment decisions.
VIJAYA - Fundamental Analysis: Financial Health & Valuation
Back to ListFundamental Rating: 3.8
| Stock Code | VIJAYA | Market Cap | 10,113 Cr. | Current Price | 981 ₹ | High / Low | 1,192 ₹ |
| Stock P/E | 67.9 | Book Value | 82.3 ₹ | Dividend Yield | 0.20 % | ROCE | 20.2 % |
| ROE | 18.1 % | Face Value | 1.00 ₹ | DMA 50 | 1,001 ₹ | DMA 200 | 1,005 ₹ |
| Chg in FII Hold | -3.17 % | Chg in DII Hold | 3.26 % | PAT Qtr | 42.7 Cr. | PAT Prev Qtr | 38.8 Cr. |
| RSI | 47.0 | MACD | -14.6 | Volume | 39,155 | Avg Vol 1Wk | 1,28,780 |
| Low price | 740 ₹ | High price | 1,192 ₹ | PEG Ratio | 10.3 | Debt to equity | 0.40 |
| 52w Index | 53.3 % | Qtr Profit Var | 7.42 % | EPS | 14.4 ₹ | Industry PE | 36.0 |
📊 Core Financials
- Revenue & Profitability: Quarterly PAT improved from 38.8 Cr. to 42.7 Cr. (+7.42%), showing steady growth momentum.
- Margins & Returns: ROCE at 20.2% and ROE at 18.1% highlight strong efficiency and profitability.
- Debt Ratios: Debt-to-equity at 0.40 indicates moderate leverage, manageable but worth monitoring.
- Cash Flows: Dividend yield of 0.20% is modest, suggesting reinvestment focus rather than high shareholder payouts.
💹 Valuation Indicators
- P/E Ratio: 67.9 vs industry average of 36.0 → trades at a significant premium.
- P/B Ratio: Current Price / Book Value ≈ 11.9 → well above intrinsic value.
- PEG Ratio: 10.3 → signals overvaluation relative to growth.
- Intrinsic Value: Current price (981 ₹) appears stretched compared to fundamentals.
🏢 Business Model & Competitive Advantage
- Strong presence in healthcare diagnostics with brand recognition and expanding network.
- High efficiency ratios (ROCE, ROE) provide competitive edge.
- Moderate debt levels allow growth but require careful monitoring.
📈 Entry Zone & Long-Term Guidance
- Entry Zone: Attractive accumulation range between 940 ₹ – 960 ₹, near DMA support levels.
- Long-Term Holding: Suitable for investors seeking exposure to healthcare growth, but staggered buying recommended due to premium valuation.
✅ Positive
- Strong ROCE and ROE highlight efficiency.
- Quarterly PAT growth (+7.42%) shows steady earnings momentum.
- DII holdings increased (+3.26%), reflecting strong domestic institutional confidence.
⚠️ Limitation
- High P/E ratio (67.9) compared to industry average.
- PEG ratio of 10.3 signals overvaluation relative to growth.
- Moderate debt-to-equity ratio (0.40) requires monitoring.
📉 Company Negative News
- Stock trading below both 50 DMA (1,001 ₹) and 200 DMA (1,005 ₹), indicating weak momentum.
- RSI at 47.0 and negative MACD (-14.6) suggest bearish technical outlook.
- FII holdings decreased (-3.17%), showing reduced foreign investor confidence.
📈 Company Positive News
- Quarterly PAT improved sequentially from 38.8 Cr. to 42.7 Cr.
- DII holdings increased (+3.26%), supporting domestic confidence.
🏭 Industry
- Industry P/E at 36.0 indicates sector trades at lower multiples.
- Healthcare diagnostics sector benefits from rising demand and preventive care trends.
- VIJAYA trades at a premium, reflecting brand strength and growth expectations.
🔎 Conclusion
VIJAYA demonstrates strong fundamentals with high efficiency and steady profit growth, but trades at a significant premium compared to industry peers. Entry is advisable near 940 ₹ – 960 ₹ for long-term investors, with staggered accumulation to mitigate valuation risks. Overall, the company remains financially healthy and strategically positioned in the healthcare diagnostics sector, though valuation signals caution.
I can also highlight support and resistance levels with RSI/MACD signals to refine entry timing for VIJAYA if you’d like.